



Veracyte, Inc.
Investor Relations Department
6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VCYT

Last Trade:	7.88
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	0.09 (+1.155%)
Day Range	7.76 - 7.90
52-Week Range	4.83 - 9.71
Volume	98,565

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 1, 2017*
[Veracyte to Present at William Blair 2017 Growth Stock Conference](#)
- May 23, 2017*
[Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017](#)
- May 18, 2017*
[Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis](#)
- May 11, 2017*
[Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"](#)
- May 10, 2017*
[Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2016*
[Quarterly Report \(10-Q\)](#)